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Atrial ﬁbrillation (AF) is the most common arrhythmia in clinical settings (Fuster et al., 2001), and it is often associated with
congestive heart diseases (Issac et al., 2007). Many studies in both laboratory and clinical settings have sought to analyze the
mechanisms of AF, develop treatments based on these mechanisms, and examine atrial remodeling in chronic AF. The aim of this
paper is to analyze recent ﬁndings regarding the atrial remodeling that occurs in AF. In particular, we will describe the electrical
andstructural changes thatinvolveatrial myocytes andthe extracellular matrix. Wewillalsodescribe thegeneral classiﬁcationand
basic pathophysiology of AF and its surgical treatments.
1.ClassiﬁcationofAF
The joint American College of Cardiology/American Heart
Association/European SocietyofCardiologyproposedaclas-
siﬁcation system for AF to simplify its heterogeneous clinical
aspects and clarify its clinical states [1]. Patients are initially
classiﬁed as having a “ﬁrst detected episode of AF,” when
AF is conﬁrmed by clinicians. If a patient has two or more
episodes, the AF is classiﬁed as recurrent. Recurrent AF is
designated as paroxysmal or persistent. Paroxysmal AF is an
episode that generally continues for 7 or fewer days and ter-
minates on its own. Persistent AF usually continues for more
than 7 days without self-terminating and requires clinicians
to terminate it using pharmacological treatment or electrical
cardioversion to restore the sinus rhythm. Permanent AF is
a situation in which the sinus rhythm cannot be sustained
after cardioversion, and further medical eﬀorts are required
to restore it.
2.Pathophysiologyof AF
2.1. The Basic Mechanisms of AF. Many researchers agree
that inﬂammation [2], neurohormonal disorders [3], cardi-
ovascular diseases such as valvular diseases [4], diabetes,
hypertension, congestive heart failure, myocardial infarction
[5], and genetic factors [6] are “modulating factors” that can
induce AF.
Classically, AF mechanisms are described by the concept
of atrial ectopic foci [7], which ﬁre spontaneously in the
atrium, a single reentry circuit, or multiple reentry circuits
[8, 9]. The surgical maze procedure is designed to block
the multiple reentry circuits and create an isolated electrical
lesion in the atrium [10]. Haissaguerre et al. reported that
triggers located in the pulmonary veins initiate most cases
of paroxysmal AF [7] ,w h i l ei ns o m ec a s e st h et r i g g e r ,s u c h
as a venous remnant in the left atrium (LA) and superior
vena cavae, occurs outside the pulmonary vein. This ﬁnding
supports the idea that a pulmonary vein isolation technique
c a nc u r ep a r o x y s m a lA Fi nm o s tc a s e s .
Wyse and Gersh summarized the mechanisms of AF
schematically [11]. In the basic scheme, a trigger and sub-
strate invoke reentry in the atrium, and the ﬁring of a focus
leads directly to AF. AF itself leads to electrophysiological
and structural atrial remodeling and produces modulating
factors that continue to initiate AF, leading to permanent AF.
Numerous factors, such as triggers, substrates, modulating
factors, AF itself, and atrial remodeling greatly impact one
another and the perpetuation of AF. Many experimental and2 ISRN Cardiology
clinical studies on the mechanisms of AF have led to numer-
ous theories and insights. However, the factors that induce
AF are very complicated, and AF still remains only partially
understood.
2.2. Atrial Remodeling of Chronic AF. There are many papers
on the electrophysiological and structural atrial remodeling
that takes place in chronic AF patients. In particular, dra-
matic structural changes in the atrial myocytes and extra-
cellular matrix (ECM) have been demonstrated along with
changes in the electrical properties of myocytes. Paroxysmal
AF sometimes leads to permanent AF, and the elucidation of
these changes could help us understand the mechanisms by
which perpetual AF is established.
2.3.Electrical Changes. Transmembrane ioniccurrentsplaya
crucialroleinthemechanisms ofAFandimpact thecontrac-
tion of atrial muscle. Many kinds of transmembrane ionic
currents have been reported, including the inward rectiﬁer
potassium current (IK1), sodium current (INA), transient
outward potassium current (Ito), ultrarapid component of
IK(IKur), rapid component of IK (IKr), slow component of
IK (IKs), inward L-type Ca2+ current (ICa), and transient
inward Na+/Ca2+ exchanger (NCX). The action potential
(AP) and action potential duration (APD) in atrial myocytes
dependonthebalancebetweentheinwardandoutwardionic
currents; this balance aﬀects the refractory period and may
be useful for the prevention of AF [9].
Many studies on AF animal models and human patients
describe abnormal ionic currents in AF. Li et al. found de-
creases in Ito, ICa,a n dIKs and increases in the NCX current,
in the atrium of a dog rapid ventricular pacing model that
induced heart failure [12]. On the other hand, in a dog
atrial pacing model, Yue et al. demonstrated decreases in
Ito, ICa that were similar to the dog heart-failure model,
but without a signiﬁcant change in IKs [13]. Regarding INA,
Gaspo et al. reported that the INA density was reduced in
a dog atrial pacing model, in a patch-clamp study [14]. In
addition, although the eﬀective refractory period (ERP) and
APD were decreased by rapid atrial pacing [13, 15], in a ven-
tricular rapid pacing model the APD either did not change
(slow rate) or increased (faster rate) [12], and the ERP
showed no change [16].
Thus, there are discrepancies between the atrial pacing
model and ventricular pacing model in terms of ionic
change and the AP of atrial myocytes. It is clear that the
mechanisms are quite diﬀerent between AF that is based
on heart failure and that originating from the atrium.
Thus, diﬀerent treatments are used for AF cases of diﬀerent
etiology. Van Wagoner et al. reported a signiﬁcant reduction
in ICa,n oc h a n g e si nC a 2+ channel performance, and a corre-
lationbetweenthe preoperativeICa density and theincidence
of postoperative AF, using isolated human atrial myocytes
[17]. In another human study, Bosch et al. demonstrated a
marked shortening of the APD, a reduction in ICa and Ito,
and an increase in IK1 [18].
We summarized the abnormalities in the ionic cur-
rents in AF in animal and human studies and found that
a reduction of ICa and Ito is common. The relevance of these
reductions to the maintenance of AF was determined by
Nattel [9]. AF inducesCa2+ entry into the cytoplasmof atrial
myocytes through Ca2+ cannels, leading to a high concentra-
tionofCa2+ inthecell[19],which threatenscellviability.The
cell protects itself from further Ca2+ loading by inactivating
ICa [20] and reducing the levels of mRNA [21] and proteins
[13,17,18]r es pon s iblef ortheICa.H o w ev er ,r educingtheICa
leads to reductions in APD and ERP, resulting in the induc-
tion and maintenance of AF. This was conﬁrmed by Ausma
et al., who showed by electron microscopy that signiﬁcant
increases in Ca2+ deposits were visible at the sarcolemma, T-
tubes, and mitochondria of atrial cardiomyocytes, in a goat
atrial rapid pacing model [22].
2.4. Structural Changes. In chronic AF, the most dramatic
change is the dilatation of the atrium wall by mechanical
stretching, which is induced by hemodynamic overload [23,
24]. Furthermore, left atrial enlargement has been proposed
to be closely related to atrial diastolic [25] and systolic
dysfunction [26]. This prolonged mechanical stretching in-
duces changes in the expression and localization of atrial
myocardial proteins, in the ECM, and in electrophysiological
activity, and some of these changes may be irreversible [27].
In this section, we analyze the structural changes associated
withAF,asdeterminedfromanimal experimentsandhuman
tissues (Table 1).
2.5. Changes in Cardiomyocytes in AF Patients and
Animal Models
2.5.1. Human Studies. Studies to determine the atrial struc-
tural changes in humans are limited, and further studies are
needed to clarify the mechanisms of human AF. Cardiac
muscle cells of the left atrial tissue in mitral valvular dis-
ease show hypertrophy and, particularly in ﬁbrotic areas,
structural changes such as a proliferation of Z-band mate-
rial, cytoskeletal ﬁlaments, myoﬁbrillar loss, a prolifera-
tion of elements of free and extended junctional sarco-
plasmic reticulum, variations in the size and number of
mitochondria, the appearance of abnormal mitochondria,
dissociated intercellular junctions, theformation ofspherical
microparticles, and an accumulation of lysosomal degrada-
tion products [28]. These degenerative changes are reported
in several papers [29, 30]. However, the probability of
hypertrophy of atrial myocytes in cases of lone AF is not
high.
Incontrast,lymphomononuclearinﬁltrateswithnecrosis
oftheadjacentmyocytesareoftenseenintheatrial˜myocytes
of lone AF [31]. Although the atrial myocytes in AF undergo
degenerative changes, the pathological changes are sec-
ondary, and it is unknown whether there is a close rela-
tionship between the degenerative changes and AF. Rabine
et al. reported a relationship between degenerative changes
and electrical function [30], but the primary reasons for AF
remain unclear. Nevertheless, changes in myocytes, such as
their stretching, may greatly impact the structural changes
and calcium homeostasis [32].ISRN Cardiology 3
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2.5.2. Animal Studies. Several papers describe the induction
of chronic AF by rapid pacing and examine the ultrastruc-
tural changes in the atrium using a dog [15, 39–41]o rg o a t
rapid pacing model [42, 43]. In the dog experimental model,
cell loss, degenerative changes including the disruption of
sarcomeres, [44] loss of myoﬁbrils, and band contraction
necrosis [16] were found, accompanied by excessive ﬁbrosis
[41], enlargement of the atrium [40], increased mitochon-
drial size, and disruption of the sarcoplasmic reticulum
[15]. Furthermore, the fast-type cardiac myosin alpha heavy
c h a i n ,as t r u c t u r a lp r o t e i n ,s w i t c h e dt ot h es l o wb e t ah e a v y
c h a i ni s o m e ri na t r i a lm y o c y t e s[ 45]. In a goat chronic AF
model, Ausma et al. demonstrated signiﬁcant changes in
cellular substructures, such as the accumulation of glycogen,
fragmentation of sarcoplasmic reticulum, homogeneous dis-
tribution of nuclear chromatin, changes in mitochondrial
shape and size, loss of myoﬁbrils, and increased cell size.
Inthegoatpacingmodel,changescharacterizingtheded-
iﬀerentiationofatrial myocytewere demonstrated,including
the disappearance of cardiotin, titin, and desmin at the
intercalated disk, and the reexpression of α-smooth muscle
actin, a feature of embryonic cardiomyocytes [46]. In addi-
tion, Dispersyn et al. reported that the histological changes
in the chronic ﬁbrillating atrial myocardium in the goat
rapid pacing model were similar to those seen in chronic
human hibernating left ventricular myocardium [47]. These
ﬁndings may indicate that ischemic changes induced by
tachypacing, thatis, occasional microcirculatory dysfunction
in the atrium, may inﬂuence structural changes in the AF
atrium.
Some degenerative changes seen in animal models are
similar to those seen in human AF, but there are no reports
in animal models describing the accumulation of lysosomal
degradationproducts, which is the most typicaldegenerative
change in the human atrium [48]. Furthermore, there are
no reports of human cases showing the dediﬀerentiation
of atrial myocytes that was demonstrated in the goat atrial
ﬁbrillation model. In human AF, there is a large quantity of
inducer, such as a trigger and modulating factor, whereas in
animal models the inducer is only the high pacing rate of the
atriumorventricle.Becausetheetiologyoftheanimal model
is quite diﬀerent from that of human AF, the animal high-
rate pacing models may not mimic human AF completely.
However, the animal high-rate pacing model is the only one
available for experimentally reproducing AF, and it has been
very useful for investigating AF’s pathophysiology.
In addition to elucidating the structural changes that ac-
company chronic AF, to know at what point AF becomes
incurable, it is important to learn the time course of these
changes and when they become irreversible. In a 7-hour
atrial pacing dog model, atrial electrical remodeling starts
within 30 minutes of very rapid pacing; this remodeling is
reversible,becauseverapamilblocksit[53].Ina1-weekatrial
pacing goat model, homogeneous chromatin distribution
and gradual changes in the mitochondria and sarcoplas-
mic reticulum were found [43]. At this stage, electrical re-
modeling is reversible, but some ultrastructural changes
may not be, because myocytes showed the ﬁrst cellular
changes, as described above. Because of the reversibility of
electrical remodeling at this stage, cardioversion is eﬀective
for recovering the sinus rhythm, but AF may recur if the
ultrastructure of the atrium remains abnormal. In the goat
pacing model, over the long term (more than 5 weeks of
pacing), the cellular and extracellular changes become so
severe that they may be irreversible [16]. On the other hand,
Ausma [27] reported that electrical and structural remod-
eling after prolonged AF (4 months) was reversible in a
goat right atrium pacing model. The ERP was normal 2
months and sinus rhythm 4 months after the end of the
inducedAF.However,althoughsomeultrastructuralchanges
(atrial myocyte diameter, number of myocytes with severe
myolysis and Connexin 40) returned to normal, the ﬁbrosis
and changes in some structural proteins remained abnormal,
and paroxysmal AF episodes occurred after the pacing. This
report indicates that the remaining ultrastructural changes
have the potential to induce the recurrence of AF, despite the
complete reversal of the electrical changes.
H o w e v e r ,t h et i m ec o u r s eo fc h a n g e si nt h ep a t h o p h y s i -
ology of human AF has not been demonstrated. In humans,
inducers of AF include volume-pressure overload, such as
heart failure, and cardiac diseases such as valvular and
coronary artery diseases, not rapid atrial pacing. Therefore,
there is no scientiﬁc basis for the reversibility of electrical
and structural remodeling in humans that could provide
information for the eﬀective treatment of AF.
2.6. Changes in Intercellular Connections: Gap Junctions. In
myocytes, the electrical conductivity between cells is sus-
tained by the Connexin located in the gap junctions. This
conductivity is responsible for the regular heart rhythm and
synchronous contraction. Connexin is expressed in every tis-
sue and organ and consists of multiple subtypes; 20 subtypes
of Connexin have been found in mouse and 21 in human
[54]. In particular, Connexins 43, 40, and 45 are expressed in
the human right atrium [55, 56].
In chronic overload of the atrium in a rat myocardial
infarction model, the lateral membranes of myocytes show
high levels of nonphosphorylated Connexin 43 [35]. In the
high-rate pacing goat model, the homogeneous Connexin
40 distribution pattern changed signiﬁcantly and became
heterogeneous, that is, a mixture of Connexins 40 and 43
with increasing duration of the atrial pacing. In contrast,
the regions in which Connexin 43 was the sole Connexin
remained unchanged [57]. A reduction in Connexin 40 in
a chronic AF goat model was observed in another study
[27], and this was also seen in a canine model [39]. Thus,
Connexin remodeling has been seen in all animal models
of chronic AF. In samples from human AF patients, several
studies have reported that Connexin 40 is highly expressed
on the lateral membrane of atrial cells [33, 36]. On the
other hand, Kostin et al. reported the lateralization of
Connexins 43 and 40 in human samples but observed that
the expression of Connexin 40 and 43 decreased in the
AF atrium [37]. Some studies agree with this ﬁnding for
Connexin 40 expression [34]. In contrast, two others report
that the expression of Connexin 43 does not change in AF
patients [36].ISRN Cardiology 5
There are many discrepancies among the studies on
Connexin 40 and 43 expression and localization in human
AF. These discrepancies may be owing to diﬀerences in the
patients’background,forexample,theirage,theirdegreeand
duration of AF, whether the experiments were performed
after a surgical procedure or not, and diﬀerences in the
location of the tissue examined. Moreover, in animal AF
models, AF is induced via many disparate routes, including
by ventricular tachypacing in a congestive heart failure
model, by atrial tachypacing an atrial tachycardia model, by
myocardial infarction, and by hypertension, in dogs [39],
goats [27, 38, 57], and rats [35]. In humans, most cases
of AF are caused by mitral valve disease [58]o ri s c h e m i c
cardiomyopathy [59]. Therefore, the animal models are not
completely relevant to human AF. Consequently, there are
large discrepancies between the results from human studies
and animal experiments regarding the histological and mol-
ecular changes in AF.
Nevertheless, the mechanism of Connexin remodeling is
considered a key factor in the primary mechanisms underly-
ing AF. Further studies of Connexin 43 and 40 are needed to
clarify the mechanisms of Connexin remodeling and its role
in human AF.
2.7. Changes in Extracellular Matrix. Changes in the extra-
cellular matrix are quite dramatic in AF patients, and they
have been described in many papers. Fibrosis is a typical
histological change in human AF [37, 49] and in dog and
[16,41,60,61]ratAFmodels[52].Fibrosisisthoughttobea
keyfactor in theAF-associated remodeling of Connexins and
electrical conduction [35, 62]. However, in one study using
a canine model of heart failure induced by right ventricle
rapid pacing, the total atrial collagen contentdid not change,
althougha disarray ofcollagen ﬁberswas demonstrated [51].
The maintenance of total collagen content was attributable
to the model being a heart failure model rather than an
atrial pacing model, and the report also demonstrated that
collagen synthesis correlated well with the left atrial wall
tension index. In particular, the expressions ofcollagen type-
1, which is the main collagen in heart [37], and collagen VI
[49]w e r es i g n i ﬁ c a n t l yd i ﬀerent in the atrium of AF patients
compared with sinus rhythm patients. On the other hand,
Li et al. reported signiﬁcant interstitial ﬁbrosis in a dog
model of heart failure induced by rapid ventricular pacing,
compared with a rapid atrial pacing model [16].
Recent reports indicate that serum markers of collagen
type-1 are critical parameters for distinguishing paroxysmal
and persistent AF [50]. This important ﬁnding enabled AF
to be diagnosed easily by a noninvasive method, serum sam-
pling. However, because the serum levels of these collagen
markers may also be elevated in liver ﬁbrosis, systemic
sclerosis, and other collagen diseases [63, 64], it is necessary
to check not only the serum markers but also histological
changes to diagnose the AF stage.
In general, Matrix metalloproteinases (MMPs) can de-
grade almost all ECM proteins and thereby control tissue
remodeling in both normal and diseased organs [65–67].
Tissue inhibitor of matrix metalloproteinases (TIMPs) can
inhibit the activity of MMPs [68]. A typical histological
change in the AF atrium is ﬁbrosis, as mentioned above,
and its occurrence may depend on the balance between the
expression of MMPs and TIMPs, as it is in other organs. Sev-
eral reports have demonstrated that a disturbed MMP/TIMP
system is a major reason for the ﬁbrosis observed in left
ventricular heart failure [69].
Several papers have described changes in MMPs in AF.
MMP-9 and MMP-2 are overexpressed in the atrium in a
canine model induced by right ventricle rapid pacing [51].
On the other hand, in a rat myocardial infarction model,
MMP-7 was overexpressed in the atrium [52]. In one human
study, Polyakova et al. reported that MMP-2 and -9 were
signiﬁcantly increased in AF patients compared with sinus
rhythm patients [49], but in another, no diﬀerence in MMP-
9 was found between these patient groups [70]. Clearly,
there are great discrepancies inthe MMP expression patterns
reported, and comparisons among these studies are not
meaningful, because of the diﬀerent species, diﬀerent back-
ground diseases, and stages of AF studied.Thus, experiments
using similar conditions, including the same experimental
species, background diseases, and AF stage, are needed to
clarify the changes in MMPs. Nevertheless, it is safe to say
thatMMPs show signiﬁcant changes in AFthatcoincidewith
dramatic structural changes in the atrium.
Regrettably, the situation is similar for studies of TIMP
changes. In a human study, serum TIMP-1 showed signiﬁ-
cant changes [50], but another paper reported no change in
TIMP-1 when human tissue samples were analyzed [70].
Another paper showed signiﬁcant AF-associated overexpres-
sion of TIMP-1 but no signiﬁcant change in TIMP-3 or -4
[49]. Nevertheless, we speculate that the MMP/TIMP system
in the AF atrium is damaged, and this damaged system leads
to signiﬁcant atrial ﬁbrosis (Table 2).
Other factors that can regulate ECM remodeling include
reversion-inducing cysteine-rich protein with Kazal motifs
(RECK)[71]andtransforming growthfactor(TGF-β1)[72].
Polyakova et al. reported that the expression of RECK, an
alternative MMP inhibitor, increased and that the levels of
both TGF-β1 and Smads were high in AF patients compared
with sinus rhythm patients. They concluded that RECK and
the TGF-β1-Smads pathway are important for ECM remod-
eling in the AF atrium [49]. In addition, in a dog ventricular
tachypacing model, TGF-β1 increased in the atrium [61].
Another proﬁbrotic molecule, angiotensin II (AT-II), is
well known to be involved in organ ﬁbrotic changes, such
as hypertensive heart disease [73], chronic heart failure [74],
myocardial infarction [75], and cardiomyopathy [76]. In
a dog ventricular tachypacing model, the tissue atrial AT-
II levels increased, and an ACE inhibitor could prevent
this increase [60]. Another paper showed that the tissue
concentration of AT-II in the atrium increased, reaching
a maximum level at 24h, and that this increase was slow
compared with the increase in the left ventricle, in a dog
ventricular tachypacing model [61]. AT-II promotes inter-
stitial ﬁbrosis and plays crucial roles in atrial remodeling in
AF.Moreover,AT-IIcanactivatetheTGF-β1-Smadspathway,
which promotes the expression of collagen type I and colla-
gen type II [77].6 ISRN Cardiology
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The phenomenon of ﬁbrosis in the atrium is secondary
to AF, and the MMP/TIMP system, RECK, and the TGF-β1-
Smads pathway may be the primary eﬀectors of the ﬁbrosis.
These mechanisms aﬀect each other, adding complexity to
the situation. Moreover, other primary mechanisms might
also be involved in ﬁbrosis. Further studies are needed to
clarify the mechanisms of ﬁbrosis and ECM remodeling in
AF.
2.8. Apoptosis. Apoptosis plays a key role in the mechanism
of organ failure in several diﬀerent organs [78]a n di nA F .I n
a sheep elevated blood pressure model, apoptosis increased
in the atrium [79], and in a pig atrial tachypacing model,
apoptotic changes were found in the atria [80]. Cardin et al.
demonstrated ina canine ventriculartachypacing model that
apoptosis, with an elevated ratio of the proapoptotic protein
Bax to the antiapoptotic protein Bcl-2, increased after 24
hoursofventriculartachypacing;thischangewasmaintained
for one week and then declined to baseline [81]. This study
also showed that the apoptotic changes led to interstitial
ﬁbrosis that peaked at 5 weeks [81]. Therefore, a large quan-
tity of atrial myocytes may be removed by apoptosis in the
initial phase of AF and replaced, subsequently,by ﬁbroblasts,
which express collagen type-1.
In a goat atrial pacing model that extended 9–23 weeks,
no apoptotic changes were observed in the atrium, based
on the levels of Bcl-2, P53, and PCNA, although the atrium
showed ﬁbroticchanges [47].This papersupportstheabove-
mentioned hypothesis that ﬁbrosis results from the balance
of MMPs and TIMPs. On the other hand, in samples of
patients who had suﬀered from AF for at least 1 month,
a high percentage of abnormal myocytes was found; most
were TUNEL-positive cells that showed increased caspase-
3 expression, decreased BCL-2 expression, and unchanged
Bax expression [82]. In spite of some discrepancies between
humans and animal models, both lines of evidence indicate
that apoptosis may play a large role in the structural remod-
eling of AF.
3.AtrialFibrillationafter CardiacSurgery
AF is a common complication after cardiovascular surgery
[83]. The incidence of AF after heart surgery is 10% to
65% and is associated with an increased the risk of stroke
[84]. Postoperative AF prolongs the duration of the hospital
stay after surgery [85], so its prevention and treatment are
important for shortening the time a patient must remain
in the hospital. Furthermore, the etiology of AF after an
operation is apparently quite diﬀerent from that of AF in
non-post-operative patients. It is multifactorial, and it is not
understood clearly, so its prevention and treatment are still
unsatisfactory. In this section, we will summarize what is
known about the mechanisms of AF after cardiac surgery.
Several possible pre-operative and postoperative mech-
anisms have been proposed to explain postoperative AF. In
the pre-operative stage, advanced age [86, 87], genetic pre-
disposition [88],and thenonuse ofa beta-adrenergicblocker
[86, 87] have all been shown to correlate with an increased
incidence of postoperative AF. At the molecular level,
Gaudino et al. demonstrated that the likelihood of postop-
erative AF is increased by a 174 G/C interleukin-6 promoter
gene variant and high serum levels of interleukin-6 and ﬁ-
brinogen and that the GG genotype is an independent pre-
dictor [88].
In addition, in the postoperative stage, inﬂammation in-
duced by heart surgery plays an important role in initiating
AF.Inacaninemodel,Tselentakisreportedthatacuteinﬂam-
mation slows conduction in the atrium anisotropically and
inducesreentry [89].M or eo v er ,in vasi v esurgery ,suc hasper-
icardiotomy or atriotomy, induces inﬂammation and leads
to inhomogeneous atrial conductionand prolongationof AF
in a canine model; this phenomenon is blocked by an anti-
inﬂammatory drug [90]. Bruins et al. reported that inter-
leukin-6, C-reactive protein (CRP), and complement-CRP
complex, respectively, reached their maximum levels at 6
hours, two days, and two to three days after surgery [91].
Furthermore, an elevated white blood cell count, a common
marker of inﬂammation, is an independent predictor of
postoperative AF [87, 92]. In addition to these parameters,
other mechanisms that may contribute to the incidence of
postoperative AF include atrial oxidative stress [93], postop-
erative complications [86, 87], and impaired renal function
following heart surgery [94].
By contrast with the other mechanisms mentioned, Con-
nexin appears to play a role in postoperative AF as well as
other etiologies. One paper showed a signiﬁcant increase
in the expression of Connexin 40 in patients who suﬀered
from AF after coronary artery bypass grafting [59]. Similarly,
Dupont et al. reported that Connexin 40 mRNA and protein
were expressed at high levels after coronary artery bypass
grafting and that the protein had a heterogeneous dis-
tribution, although neither Connexin 43 nor 45 changed
[36]. Another paper demonstrated that the postoperative
expressionlevelsofConnexin40and43diﬀeredconsiderably
for surgeries involving cardioplegic arrest or a beating-heart
technique, and this diﬀerence might aﬀect the incidence
of postoperative AF [95]. Cardiovascular surgeons should
be aware that open-heart surgeries bring about molecular
changes that can lead to complications such as postopera-
tive arrhythmias and that the degree of molecular change
depends on the method of the operation.
4.TheMechanisms of“AFBegetsAF”
We have summarized and discussed the histological and
electrical eventsoccurring in chronic AF. Another important
aspect, in terms of preventing permanent AF, involves
elucidating the mechanisms that lead from paroxysmal AF to
permanent AF. The mechanisms underlying this change are
likely to be very complicated, but several review articles have
presented hypotheses to account for them [9, 11, 96].
We have summarized the mechanisms for the progres-
sion of paroxysmal or persistent AF in Figure 1.O n c eA F
is initiated by a trigger or substrate, the tachycardia induces
electricalremodeling.Thisbecomesaviciouscirclethatleads
to permanent changes. In addition, Ca2+ loading, which is8 ISRN Cardiology
ECM remodeling
Single circuit reentry
Multiple circuit reentry
Af tachycardia
Ca2+ loading Ica ↓
Cytosolic Ca2+ ↓
APD ↓, ERP ↓WL ↓
Atrial myocyte contraction ↓
Myolysis
Abnorm m ality of it cho on d r i a
LA dilatation
LA wall stretch
Collagen type 1 ↑
AT-II ↑ MMP2 ↑
TIMP?
RECK ↑
TGF-β1 ↑
Smads↑
Electrical conduction
disturbances
Substrate Trigger
Ectopic focus
(pulmonary veins)
Modulating factor
Inﬂammation
Neuro hormonal
Cardiovascular disease
Genetics
Atrial myocyte remodeling
Dediﬀerentiation Apoptosis
Electrical remodeling Abnormality of Connexin
Figure 1: Mechanism of “AF begets AF.”
induced by tachycardia, attenuates contraction of the atrial
myocytes, resulting in left atrial (LA) dilatation, which can
be a type of substrate in AF.
The structural remodeling of atrial myocytes involves
dramatic histological changes, such as abnormal mitochon-
dria and the dediﬀerentiation of atrial myocytes, and these
changes can also aﬀectmyocytecontraction. InECMremod-
eling, collagen type-1 synthesis is upregulated by AT-II, the
MMP/TIMP system, RECK, and the TGF-β1-Smads path-
way. The increase in collagen type-1 induces LA dilatation
and disturbances in the electrical conduction between atrial
myocytes. As described above, there is a complicated net-
work among electrical remodeling, atrial myocyte structural
remodeling, and ECM remodeling. Once AF is initiated by
some trigger or substrate, it may become permanent stage
viathecollectiveandintertwined eﬀectsofthesecomplicated
mechanisms. This process is called “AF begets AF.”
5.FutureProspects
5.1. ECM Cellular Connection. Various studies have demon-
stratedthatthecontentoftheECM,ﬁbrosis,theMMP/TIMP
system, and other factors promote interstitial ﬁbrosis. How-
ever, there are no reports on the ECM cellular connection
in AF. Another key to the mechanisms of AF may be cell-
matrix communication, in which integrin is the most
important molecule for cell-matrix adhesion. In the absence
of cell-matrix interactions through integrin, cells of every
type, except blood cells, fall into a type of apoptosis called
“anoikis.”Cellsalsoexertvariousfunctionsthroughintegrin-
mediated cell-matrix interactions, including proliferation,
diﬀerentiation, motility, and protein production. In AF
patients, the connection between cells and the ECM might
be disturbed, leading toabnormal contractionand distressed
electrical conductance in the atrium. Moreover, nobody
knows which integrin subtypes exist on the membrane of
atrial myocytes,althoughtheintegrin subtypesin ventricular
myocytes have been well elucidated. In addition, the roles
of Laminins, which are integrin antagonists, are not fully
understood in AF.Aswith the ECM cellularcommunication,
there are no reports on the intercellular signaling pathways
involving integrins in AF. Studies on the roles of ECM
cellularcommunicationand theintercellularsignal pathways
in AF may elucidate the primary mechanisms of structural
remodeling in chronic AF. It is important to determine
which changes initiate atrial remodeling, which ones have
secondary eﬀects.
5.2. Establishment of Clinical Criteria to Determine Whether
AF Is Reversible. In clinical settings, decisions about the
severity of AF are determined by the result of treatments,
such as the eﬀectiveness of cardioversion, and the duration
of AF. It is important to establish a set of criteria, such as
histological, molecular, and electrical parameters, by which
clinicians can decide whether AF is reversible or not. In
addition, developing criteria that could allow noninvasive
methods, such as MRI, to be used for diagnosing the severity
of AF would be extremely beneﬁcial. If we can elucidateISRN Cardiology 9
criteria to determine when AF is curable by medication or
ablation,itwill greatlyadvance thepreventionand treatment
of AF.
6.Conclusion
Basic researchers have performed many excellent studies on
AF, but controversies remain. To resolve these controversies,
researchers need to analyze the complicated mechanisms of
AF through carefully controlled, systematic experiments.
Clinicians havevaliantlysoughttotreatAFbydeveloping
surgical methods, ablation-based catheter techniques, and
pharmaceuticals. However, the prevention and treatment
of AF remain unsatisfactory. The results of basic research
that will allow clinicians to determine whether patients have
reversible or irreversible AF and which treatment is appro-
priate for a given patient are urgently needed. Furthermore,
such studies may lead to new strategies for preventing or
curing AF completely.
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